Pediatric Growth Hormone Deficiency Market is segmented By Product (Recombinant Human Growth Hormone, Human Growth Hormone Analogs, Long-acting Growth....
Market Size in USD
CAGR5.3%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.3% |
Market Concentration | High |
Major Players | Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Merck KGaA (EMD Serono), Sandoz International GmbH |
The pediatric growth hormone deficiency market is estimated to be valued at USD 4.74 Bn in 2024 and is expected to reach USD 6.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031. The pediatric growth hormone deficiency market has been witnessing steady growth over the past few years and increased awareness regarding treatment of pediatric growth disorders is expected to drive further growth.